Chris Nolet serves as Executive at Revance Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Chris Nolet has executed 9 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on May 1, 2024 involved receiving (via award) 15,000 shares valued at $0.
Chris Nolet currently holds 43,606 shares of Revance Therapeutics, Inc. (RVNC), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Chris Nolet has been a net neutral trader of RVNC stock. They have purchased $0 and sold $0 worth of shares.
Chris Nolet's most recent insider trade was on May 1, 2024, when they sold 15,000 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Jan 12, 2023 | PTE | $0 | Option Exercise | 36,497 | $N/A | Discretionary |
| Oct 12, 2022 | JSPR | $0 | Award | 32,500 | $N/A | Discretionary |
| Oct 1, 2022 | PTE | $0 | Award | 50,900 | $N/A | Discretionary |
| May 4, 2022 | RVNC | $0 | Award | 6,059 | $N/A | Discretionary |
| May 5, 2021 | RVNC | $0 | Award | 4,013 | $N/A | Discretionary |
| May 14, 2020 | RVNC | $0 | Award | 6,000 | $N/A | Discretionary |
| Jul 16, 2019 | RVNC | $0 | Award | 9,000 | $N/A | Discretionary |